Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > FcRn > FRT-01

Human FcRn binding Kit (TR-FRET)

For research use only.

Order Now

Product Details
Assay TypeInhibition-TR-FRET
AnalyteFcRn binding component
Format100T, 500T
ReactivityHuman
Regulatory StatusRUO
SensitivityIC50=20.14μg/mL
Standard Curve Range0.24 μg/mL-1000 μg/mL
Assay Time1 hr
Suitable Sample TypeFor the binding of IgG Fc region to the human FcRn receptor
Sample volume10 μL
Materials Provided
IDComponentsSize
FRT01-C01Human FCRN&B2M Heterodimer Protein Europium-chelate2.7 μg
FRT01-C02FA labeled human IgG antibody2.4 μg
FRT01-C03Human IgG standard200 μg
FRT01-C04Sample Dilution Buffer10 mL
FRT01-C05Detection Buffer10 mL
This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
  • Background
    FcRn is a heterodimer comprising a β2-microglobulin (β2m) light chain and a major histocompatibility complex class I-like heavy chain. It is widely accepted that the interaction of IgGs with the Fc receptor (FcRn) plays a critical role in regulating IgG homeostasis in vivo. FcRn interacts with the CH2-CH3 portion of the Fc domain of IgGs in a tightly regulated pH-dependent manner with high affinity binding occurring at an acidic (pH=6) and weak to no binding interactions as the pH is raised to neutral (7.4). FcRn is responsible for the extended serum half-life of IgG and also serum albumin, and for the transport across endothelial and epithelial barriers, increasing the overall bioavailability of IgG and serum albumin. The binding affinity between FcRn and IgG are commonly used to characterize the metabolic levels of antibody drugs.

    The Human FcRn Binding Kit (TR-FRET) can detect the binding of IgG Fc region to the human FcRn receptor in homogeneous system within 0.5-1 hours. it is high sensitive, short detection time and easy to use.

  • Application

    The kit is developed for the binding of IgG Fc region to the human FcRn receptor. It is used as a universal detection tool to identifying the ability of antibody drugs to bind to FcRn.

    It is for research use only.

  • Storage
    The unopened kit should be stored at -20°C upon receiving.

    Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table.

  • Assay Principles
    This Human FcRn binding Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use the mixture of biotinylated FcRn and Europium-chelate labeled streptavidin as the donor, FA labeled Human IgG1 antibody as the acceptor. Firstly, mix the sample or Human IgG standard in the kit with Human FCRN&B2M Heterodimer Protein Europium-chelate (Donor) and incubate at room temperature for 0.5 hour. Then, add FA labeled human IgG antibody (Acceptor) and incubate at room temperature for more than 0.5 hour. Use the TR-FRET module of a microplate reader to read the fluorescence signal at 665nm and 620nm. When the sample does not contain FcRn binding component, the donor and acceptor are in close proximity because of the binding of FcRn and FA labeled Human IgG1 antibody. The 620nm signal emitted by the donor under specific light source excitation is received by the acceptor, emitting a 665nm signal. When the sample contains FcRn binding components, the components compete with the binding between the donor and acceptor and thereby prevents FRET from occurring. Calculate Ratio based on the formula Ratio = "Signal 665 nm" /" Signal 620 nm " × 10^4. The Ratio value is negatively correlated with the antibody content in the sample.

    Assay Principles

  • Clinical and Translational Updates

Comments (0)

Price(USD) : $750.00

Price(USD) : $2500.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:6 Details
  • Latest Research Phase:Phase ?

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message